
J&J forecasts $2.5B COVID vaccine sales this year, lagging rivals
NY Post
Pharmaceutical giant Johnson & Johnson revealed Wednesday that it expects to take home about $2.5 billion from COVID-19 vaccine sales in 2021, far lower than estimates from its jab rivals Moderna and Pfizer.
Pfizer and Moderna have previously forecast $26 billion and $19.2 billion in annual sales of their vaccines, respectively. Those two-shot vaccines were approved by US regulators last year, while J&J’s one-shot vaccine was approved earlier this year. J&J’s vaccine has been hit by various setbacks, including concerns over rare but severe side effects that appear to be linked to the vaccine as well as questions over the shot’s effectiveness against new variants of the virus.More Related News

Imagine if Allied intelligence had located Adolf Hitler in late May 1944 and killed him before the Normandy invasion. Imagine that in the same hour, strikes eliminated Hitler’s designated successor, the head of the German Armed Forces High Command, the chief operational planner of the war effort, Field Marshal Erwin Rommel, responsible for defending Western Europe, and the rest of Germany’s field marshals and senior commanders.












